Bayer AG (BAYRY) reported second-quarter 2024 core earnings of 25 cents per American Depositary Receipt (ADR), on par with the Zacks Consensus Estimate. The company reported earnings of 33 cents per ADR in the year-ago quarter. Core earnings of €0.94 per share deteriorated 23% year over year due to a decline in earnings at the Crop Science Division. Total sales in the reported quarter were $12 billion (€11.14 billion), up 0.9% on a reported basis as volume growth of 1.6% and positive pricing impact of 1.5% ...

///////////// Health for all, Hunger for none Q2 2024 Investor Call A u g u s t 0 6 , 2 0 2 4 Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Thes ...

Per the data readout, the combo therapy of darolutamide and ADT significantly increased rPFS compared with placebo plus ADT. Treatment with the investigational combo was overall well tolerated and demonstrated a safety profile that was consistent with that observed in previously completed studies in advanced prostate cancer. Image Source: Zacks Investment Research Subject to approval, the company will be able to cater to individual mHSPC patient needs by tailoring customized darolutamide/ADT treatment plans ...

In the past 30 days, the Zacks Consensus Estimate for Annovis' 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has remained constant at $1.95. ANVS beat on earnings in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%. REGENERATE-PD is a phase II study evaluating the efficacy and safety of AB-1005, an investigational adenoassociated virus 2 (AAV2) glial cell line-derived neurotrophi ...

Bayer AG [BAYZF] Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Jost Reinhard - IR Conference Call Participants Emily Field - Barclays Vincent Andrews - Morgan Stanley Peter Verdult - Citibank Richard Vosser - J.P. Morgan Joel Jackson - BMO Capital Markets Florent Cespedes - ...

Bayer AG (BAYRY) reported first-quarter 2024 core earnings of 77 cents per American Depositary Receipt (ADR). The company reported earnings of 79 cents per ADR in the year-ago quarter. Core earnings of €2.82 per share declined 4.4% year over year. Total sales in the reported quarter were $14.95 billion (€13.77 billion), down 4.3% on a reported basis. On a currency and portfolio-adjusted basis, sales declined 0.6% year over year. All growth rates mentioned below are on a year-over-year basis after adjusting ...

///////////// Health for all, Hunger for none | --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company an ...

Bayer AG (BAYRY) announced positive top-line results of the phase III study, OASIS 3, evaluating the efficacy and long-term safety of pipeline candidate elinzanetant compared to placebo.Elinzanetant, a dual neurokinin-1,3 (NK-1,3) receptor antagonist, is in late-stage clinical development for the non-hormonal treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, administered orally once daily.OASIS 3 is the third phase III study in the OASIS clinical development program. The st ...

Bayer AG (BAYRY) reported fourth-quarter 2023 core earnings of 50 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 45 cents. The company reported earnings of 34 cents per ADR in the year-ago quarter.Core earnings of €1.85 per share rose 37% year over year in the fourth quarter of 2023.Total sales in the reported quarter were $12.77 billion (€11.86 billion), down 1.2% on a reported basis. On a currency and portfolio-adjusted basis, sales rose 5.5% year over year.All gro ...

Bayer (BAYRY) announced that it has acquired the exclusive marketing rights for cardiovascular candidate acoramidis in Europe from BridgeBio (BBIO) . The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.Acoramidis is an investigational, next-generation, orally-administered, highly potent small molecule stabilizer of transthyretin (TTR).  It is being evaluated for the treatment of patients suffering from transthyretin amyloid cardiomyopathy (ATTR-CM).In ...